Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
letter
. 1972 Jan;44(1):162–164. doi: 10.1111/j.1476-5381.1972.tb07249.x

Action of L-α-methyldopa-hydrazine on the blood pressure of patients receiving levodopa

D B Calne, A Petrie, Sumant Rao, J L Reid, S D Vakil
PMCID: PMC1665682  PMID: 5015036

Abstract

The blood pressure and pulse rate have been compared in a 'double blind, cross over' study involving twenty patients with idiopathic Parkinsonism receiving maximum tolerated dosage of levodopa with and without an extracerebral decarboxylase inhibitor, L-α-methyldopahydrazine. The supine and erect systolic pressures were significantly higher and the erect pulse rate significantly lower during administration of L-α-methyldopahydrazine. The implications of these observations are discussed.

Full text

PDF
162

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bloom F. E., Costa E., Salmoiraghi G. C. Anesthesia and the responsiveness of individual neurons of the caudate nucleus of the cat to acetylcholine, norepinephrine and dopamine administered by microelectrophoresis. J Pharmacol Exp Ther. 1965 Nov;150(2):244–252. [PubMed] [Google Scholar]
  2. Calne D. B., Brennan J., Spiers A. S., Stern G. M. Hypotension caused by L-dopa. Br Med J. 1970 Feb 21;1(5694):474–475. doi: 10.1136/bmj.1.5694.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Calne D. B., Karoum F., Ruthven C. R., Sandler M. The metabolism of orally administered L-Dopa in Parkinsonism. Br J Pharmacol. 1969 Sep;37(1):57–68. doi: 10.1111/j.1476-5381.1969.tb09522.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Calne D. B., Reid J. L., Vakil S. D., Rao S., Petrie A., Pallis C. A., Gawler J., Thomas P. K., Hilson A. Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J. 1971 Sep 25;3(5777):729–732. doi: 10.1136/bmj.3.5777.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. EBLE J. N. A PROPOSED MECHANISM FOR THE DEPRESSOR EFFECT OF DOPAMINE IN THE ANESTHETIZED DOG. J Pharmacol Exp Ther. 1964 Jul;145:64–70. [PubMed] [Google Scholar]
  6. Godwin-Austen R. B., Tomlinson E. B., Frears C. C., Kok H. W. Effects of L-dopa in Parkinson's disease. Lancet. 1969 Jul 26;2(7613):165–168. doi: 10.1016/s0140-6736(69)91417-2. [DOI] [PubMed] [Google Scholar]
  7. Henning M., Rubenson A. Central hypotensive effect of L-3,4-dihydroxyphenylalanine in the rat. J Pharm Pharmacol. 1970 Aug;22(8):553–560. doi: 10.1111/j.2042-7158.1970.tb10570.x. [DOI] [PubMed] [Google Scholar]
  8. MCNAY J. L., MCDONALD R. H., Jr, GOLDBERG L. I. DIRECT RENAL VASODILATATION PRODUCED BY DOPAMINE IN THE DOG. Circ Res. 1965 Jun;16:510–517. doi: 10.1161/01.res.16.6.510. [DOI] [PubMed] [Google Scholar]
  9. McNay J. L., Goldberg L. I. Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow. J Pharmacol Exp Ther. 1966 Jan;151(1):23–31. [PubMed] [Google Scholar]
  10. Ross G., Brown A. W. Cardiovascular effects of dopamine in the anesthetized cat. Am J Physiol. 1967 Apr;212(4):823–828. doi: 10.1152/ajplegacy.1967.212.4.823. [DOI] [PubMed] [Google Scholar]
  11. SJOERDSMA A., VENDSALU A., ENGELMAN K. STUDIES ON THE METABOLISM AND MECHANISM OF ACTION OF METHYLDOPA. Circulation. 1963 Oct;28:492–502. doi: 10.1161/01.cir.28.4.492. [DOI] [PubMed] [Google Scholar]
  12. Watanabe A. M., Chase T. N., Cardon P. V. Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther. 1970 Sep-Oct;11(5):740–746. doi: 10.1002/cpt1970115740. [DOI] [PubMed] [Google Scholar]
  13. Yahr M. D., Duvoisin R. C., Schear M. J., Barrett R. E., Hoehn M. M. Treatment of parkinsonism with levodopa. Arch Neurol. 1969 Oct;21(4):343–354. doi: 10.1001/archneur.1969.00480160015001. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES